AGR2 and neoplasm: This enhancing effect is contingent upon the homodimerization domain of AGR2; thus, monoclonal antibodies targeting AGR2 self-dimerization may emerge as novel therapeutic agents for tumor treatment (Guo et al., 2017) (Figure 2B).